BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioMarin Pharmaceutical readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies BioMarin Pharmaceutical's drugs r
 un\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04020055-912@assetmemo.bio
DTSTAMP:20261121T005646Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Galafold (Migalastat): Phase 3 readout est. (NCT04020055)
DESCRIPTION:Galafold (Migalastat)\, phase 3\, Fabry Disease.\nStudy: A Stud
 y to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and R
 enal Disease\nEstimated primary completion: 31 December 2026. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/migalastat#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT04020055
URL:https://assetmemo.bio/drug/migalastat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06280209-10782@assetmemo.bio
DTSTAMP:20261121T005646Z
DTSTART;VALUE=DATE:20270414
DTEND;VALUE=DATE:20270415
SUMMARY:Nivudirsen (BMN 351): Phase 1/2 readout est. (NCT06280209)
DESCRIPTION:Nivudirsen (BMN 351)\, phase 1/2\, Duchenne Muscular Dystrophy.
 \nStudy: A Phase 1/2 Study to Assess the Safety\, Tolerability\, Pharmacok
 inetics\, and Pharmacodynamics of BMN 351 in Participants With Duchenne Mu
 scular Dystrophy\nEstimated primary completion: 14 April 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/nivudirsen-bmn-351#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06280209
URL:https://assetmemo.bio/drug/nivudirsen-bmn-351#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02724228-10775@assetmemo.bio
DTSTAMP:20261121T005646Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:VOXZOGO (Vosoritide): Phase 2 readout est. (NCT02724228)
DESCRIPTION:VOXZOGO (Vosoritide)\, phase 2\, Achondroplasia.\nStudy: A Stud
 y to Evaluate Long-Term Safety\, Tolerability\, & Efficacy of BMN 111 in C
 hildren With Achondroplasia (ACH)\nEstimated primary completion: December 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/vosoritide#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT02724228
URL:https://assetmemo.bio/drug/vosoritide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04554940-10775@assetmemo.bio
DTSTAMP:20261121T005646Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:VOXZOGO (Vosoritide): Phase 2 readout est. (NCT04554940)
DESCRIPTION:VOXZOGO (Vosoritide)\, phase 2\, Achondroplasia.\nStudy: A Clin
 ical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achond
 roplasia\nEstimated primary completion: December 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/vosoritide#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT04554940
URL:https://assetmemo.bio/drug/vosoritide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06904261-912@assetmemo.bio
DTSTAMP:20261121T005646Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Galafold (Migalastat): Phase 3 readout est. (NCT06904261)
DESCRIPTION:Galafold (Migalastat)\, phase 3\, Fabry Disease.\nStudy: A Stud
 y of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease an
 d Amenable GLA Variants\nEstimated primary completion: December 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/migalastat#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06904261
URL:https://assetmemo.bio/drug/migalastat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07126262-10775@assetmemo.bio
DTSTAMP:20261121T005646Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:VOXZOGO (Vosoritide): Phase 2 readout est. (NCT07126262)
DESCRIPTION:VOXZOGO (Vosoritide)\, phase 2\, Hypochondroplasia.\nStudy: A S
 tudy of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 
 0 to < 36 Months\nEstimated primary completion: 30 June 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/vosoritide#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07126262
URL:https://assetmemo.bio/drug/vosoritide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07441876-10781@assetmemo.bio
DTSTAMP:20261121T005646Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:BMN 333: Phase 2/3 readout est. (NCT07441876)
DESCRIPTION:BMN 333\, phase 2/3\, Achondroplasia.\nStudy: Study to Evaluate
  the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Ach
 ondroplasia\nEstimated primary completion: June 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/bmn-333#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07441876
URL:https://assetmemo.bio/drug/bmn-333#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03424018-10775@assetmemo.bio
DTSTAMP:20261121T005646Z
DTSTART;VALUE=DATE:20310630
DTEND;VALUE=DATE:20310701
SUMMARY:VOXZOGO (Vosoritide): Phase 3 readout est. (NCT03424018)
DESCRIPTION:VOXZOGO (Vosoritide)\, phase 3\, Achondroplasia.\nStudy: An Ext
 ension Study to Evaluate the Efficacy and Safety of BMN 111 in Children Wi
 th Achondroplasia\nEstimated primary completion: June 2031. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/vosoritide#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT03424018
URL:https://assetmemo.bio/drug/vosoritide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07573631-10782@assetmemo.bio
DTSTAMP:20261121T005646Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Nivudirsen (BMN 351): Phase 2 readout est. (NCT07573631)
DESCRIPTION:Nivudirsen (BMN 351)\, phase 2\, Duchenne Muscular Dystrophy.\n
 Study: An Open-Label Extension Study to Evaluate the Long-term Safety and 
 Efficacy of BMN 351 in Participants With Duchenne Muscular Dystrophy\nEsti
 mated primary completion: December 2031. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/nivudirsen-bmn-351#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07573631
URL:https://assetmemo.bio/drug/nivudirsen-bmn-351#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03989947-10775@assetmemo.bio
DTSTAMP:20261121T005646Z
DTSTART;VALUE=DATE:20380531
DTEND;VALUE=DATE:20380601
SUMMARY:VOXZOGO (Vosoritide): Phase 2 readout est. (NCT03989947)
DESCRIPTION:VOXZOGO (Vosoritide)\, phase 2\, Achondroplasia.\nStudy: An Ext
 ension Study to Evaluate Safety and Efficacy of BMN 111 in Children With A
 chondroplasia\nEstimated primary completion: May 2038. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/vosoritide#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT03989947
URL:https://assetmemo.bio/drug/vosoritide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07073014-10775@assetmemo.bio
DTSTAMP:20261121T005646Z
DTSTART;VALUE=DATE:20441031
DTEND;VALUE=DATE:20441101
SUMMARY:VOXZOGO (Vosoritide): Phase 3 readout est. (NCT07073014)
DESCRIPTION:VOXZOGO (Vosoritide)\, phase 3\, Hypochondroplasia.\nStudy: Lon
 g-Term Extension Study of Vosoritide to Treat Children With Hypochondropla
 sia\nEstimated primary completion: October 2044. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/vosoritide#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07073014
URL:https://assetmemo.bio/drug/vosoritide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
